Perspective Therapeutics, Inc.
CATX
$2.16
-$0.03-1.37%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -30.96% | -15.64% | -3.60% | 1.39% | 351.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -30.96% | -15.64% | -3.60% | 1.39% | 351.13% |
| Cost of Revenue | 76.48% | 87.56% | 90.85% | 135.87% | 276.54% |
| Gross Profit | -81.54% | -93.23% | -97.33% | -148.58% | -236.87% |
| SG&A Expenses | 35.27% | 47.90% | 40.92% | 26.34% | 36.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | 200.00% |
| Total Operating Expenses | 61.78% | 72.65% | 68.58% | 61.06% | 98.97% |
| Operating Income | -64.28% | -75.30% | -71.07% | -63.15% | -89.78% |
| Income Before Tax | -117.56% | -120.33% | -103.92% | -100.39% | -69.09% |
| Income Tax Expenses | -126.72% | -126.72% | -126.72% | 20.90% | 174.75% |
| Earnings from Continuing Operations | -84.30% | -83.11% | -67.99% | -108.97% | -204.16% |
| Earnings from Discontinued Operations | 107.42% | 106.58% | 93.18% | 88.87% | -58.45% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.87% | -60.89% | -45.79% | -70.46% | -154.12% |
| EBIT | -64.28% | -75.30% | -71.07% | -63.15% | -89.78% |
| EBITDA | -100.62% | -117.37% | -116.25% | -111.92% | -88.77% |
| EPS Basic | 3.89% | 20.91% | 36.16% | 27.43% | -49.85% |
| Normalized Basic EPS | -11.30% | 12.50% | 33.27% | 41.69% | 8.95% |
| EPS Diluted | -33.77% | -13.26% | 5.99% | -6.96% | -49.85% |
| Normalized Diluted EPS | -11.30% | 12.50% | 33.27% | 41.69% | 8.95% |
| Average Basic Shares Outstanding | 35.76% | 67.17% | 109.84% | 140.75% | 130.75% |
| Average Diluted Shares Outstanding | 35.76% | 67.17% | 109.84% | 140.75% | 130.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |